RNS Number : 2594T
Hemogenyx Pharmaceuticals PLC
11 October 2017
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Director / PDMR Shareholding
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it was informed on 10 October 2017 that Adrian Beeston, Non-Executive Director, has purchased an additional 400,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 2.96p per share. Following this transaction Mr Beeston now has an interest in 6,131,969 Ordinary Shares, representing approximately 1.72 per cent. of the Company's issued share capital.
The Notification of Dealing Form provided in accordance with the requirements of MAR in relation to the transaction listed above is set out below:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
This information is provided by RNS
The company news service from the London Stock Exchange
Pumpedordumped cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk. Thankyou.